GrayMatters Health

Prism Suite.

Powered by the Brain™

GrayMatters Health offers a unique opportunity to elevate your clinical practice with the latest brain-computer interface (BCI) technology.

Introducing **Prism Suite**, powered by the world's first fMRI-informed digital biomarkers of brain activity associated with mental health disorders.

Prism changes the way patients engage with their mental health by putting them in the driver's seat, expertly guided by you, their trusted provider, This new modality, Prism self-guided neuromodulation, enables patients to learn to regulate brain activity associated with their mental health condition in the clinic and in their lives.

PRISM SUITE

Prism is a comprehensive suite of solutions for leveraging the power of the brain, featuring two protocols and a toolbox to help improve care by engaging with your patients:

- **PTSD**
  Guides patients how to down-regulate an amygdala-based biomarker to treat symptoms associated with PTSD.
- **Depression**
  Guides patients how to up-regulate the reward-system biomarker to help live better with depression.
- **Toolbox**
  Insights tool delivers data-driven analysis of each patient's performance as well as suggested topics for discussion to guide their Prism experience.

VALUE FOR YOUR PRACTICE

Operational simplicity.

Integrates seamlessly with clinic operational flow from intake to treatment. GMH provides onsite installation and training as well as in-person and remote support.

Reduced costs and expanded access to care.

A licensed healthcare professional writes the prescription for Prism and a technician administers the Prism sessions.

Growing your clinic.

Prism suite can help build a revenue-generating service line to attract patients and expand your business.

> *Since using **Prism** my quality of life has improved and my capacity to enjoy life has really opened up! I feel calmer, more in control, and am thinking more clearly.*
>
> **Prism PTSD Patient**

PTSD CLINICAL RESULTS

The multi-center clinical study[1] to evaluate the down-regulation of the amygdala-based biomarker in **Prism for PTSD** demonstrated the following results 3 months after completing the 15-session regimen (5 months from baseline):

Efficacy

- **67%** of patients overall demonstrated clinically significant PTSD symptom improvement.
- Significant improvement across all symptom clusters, including sleep, as measured by PHQ-9 and CAPS-5.
- **32%** experienced remission.
- **90%** patient compliance.

ANHEDONIC DEPRESSION CLINICAL RESULTS

The pilot study to evaluate up-regulation of the reward system biomarker with **Prism for Depression** demonstrated the following results after a 10-session regimen. Although treatment effects were observed after 10 sessions, a 15-session regimen is recommended to achieve robust and sustained clinical outcomes:

- **78%** of subjects had a clinically meaningful reduction of depression symptomsd from baseline.
- **38%** response rate of **50%** reduction in symptoms (HDRS).
- Reduction of anhedonia symptoms demonstrated by an average **6.32 score** reduction (SHAPS-C).
- **32%** remission rate
- Depression and anhedonia continued to improve from baseline to midpoint to end of treatment, suggesting further gains could be achieved with more sessions.

Safety: A majority of the reported adverse events, such as fatigue and headaches, were mild and resolved immediately after the session without any further intervention.

1 Fruchter et al. Amygdala-derived-EEG-fMRI-pattern neurofeedback for the treatment of chronic post-traumatic stress disorder. A prospective, multicenter, multinational study evaluating clinical efficacy.

Psychiatry Research, Volume 333, 2024.

2 Amital D, et al. brain sciences, Volume 15, Issue 5, 2025. Reward System EEG–fMRI-Pattern Neurofeedback for Major Depressive Disorder with Anhedonia: A Multicenter Pilot Study.

PRISM INTERVENTION

During each Prism session, the patient watches a computer simulation with animated characters, or avatars, while wearing a soft EEG cap with sensors. The sensors measure brain activity in real-time, like a fitness tracker measures heart rate.

The patient is instructed to identify a mental strategy – a personal memory, emotion or experience – to get the avatars in the computer simulation to respond. This is where the technological innovation of Prism connects with the patient. In real-time, Prism reads the signal from the EEG sensors and computes the relevant digital biomarker.

The PTSD protocol uses an amygdala-based biomarker since research has shown that PTSD is associated with hyperactivity of the amygdala. Once the patient engages with a mental strategy that lowers the level of the amygdala-based biomarker, the animated characters will gradually sit and quiet down.

The Depression protocol uses a reward-system biomarker since research has shown that the activity in this network can impact a person's ability to experience joy and motivation. When the patient finds a mental strategy that increases the level of the reward-system biomarker, the animated character does an activity with her dog.

SETUP IN THE CLINIC

All you need is a small quiet room, stationary table and chair, wired Internet connection and a trained Prism specialist to monitor the patient sessions. It is possible to monitor the patient session from a remote computer in a separate room.

Prism includes a laptop installed with the biomarker powered software, patient monitor, and Prism cloud services. An FDA-approved, off-the-shelf wireless EEG headset is provided seperately.

Installation and training are performed by the GMH team and require less than four hours. On-demand education is also available.

SCHEDULING PATIENTS FOR PRISM

- **15** sessions over **8** weeks
- **45** minutes/session
- Booster sessions as needed

fMRI-INFORMED BIOMARKER TECHNOLOGY



GAME-CHANGING INNOVATION

The company's core technology is the world's first fMRI-informed digital biomarkers associated with mental health. The proprietary EFPs (EEG-fMRI-Pattern) digital biomarkers were developed by applying advanced machine learning to register fMRI data of deep brain regions to an accessible and low-cost modality, EEG. This creates a digital biomarker that can be used in clinical practice that is informed by the high spatial resolution of fMRI.

GMH's patented biomarker technology has been extensively researched and featured in peer-reviewed publications, led by Professor Talma Hendler, MD, PhD, renowned psychiatrist and neuroscientist, and her team at Tel Aviv University.

COMPANY OVERVIEW

GrayMatters Health (GMH) is a health technology company developing and marketing an interventional psychiatry suite of solutions powered by digital brain biomarkers for personalized mental health care.

GMH is collaborating with leading mental health institutions to evaluate expanding the Prism portfolio.

INDICATION FOR USE

PTSD: Prism is a neurofeedback software device intended for relaxation and stress reduction through the use of EEG biofeedback. The device is indicated as an adjunctive treatment of symptoms associated with posttraumatic stress disorder (PTSD), to be used under the direction of a healthcare professional, together with other pharmacological and/or non-pharmacological interventions.

Depression: A neurofeedback software device using EEG biofeedback to promote relaxation, reduce stress, support well-being and can help living better with depression.